Edesa Biotech wins FDA clearance for Phase 2 vitiligo study
EDSA•The FDA cleared Edesa Biotech’s IND application for a Phase 2 study of EB06, allowing expansion to U.S. sites. U.S. enrollment is expected to begin in the first quarter of 2027, with topline results anticipated in the fourth quarter of 2027.
1. U.S. study expansion
The FDA cleared Edesa Biotech’s IND application for its Phase 2 vitiligo study of EB06, enabling the company to expand the study to U.S. sites. U.S. enrollment is expected to begin in the first quarter of 2027, and topline results are anticipated in the fourth quarter of 2027.
